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ABSTRACT
The stability of the circadian rhythm for mammals depends on the levels of serotonin and
melatonin, neurohormones that signal for lightness and darkness, respectively. Disruption in the
stability of neurohormones has been shown to be a critical factor in psychopathological disorders
in humans. For example, altering levels of melatonin in utero through administration of
melatonin or the melatonin receptor antagonist, luzindole, has been shown to cause changes in
developmental growth and adult behavior in the male rat. Analysis of relative adult hippocampal
gene expression with RT-PCR revealed differences in ARNTL expression that suggested
abnormality in clock gene expression of the rats that were prenatally exposed to altered levels of
melatonin. Differences in the degree of plasticity as suggested by previous behavior testing did
not result in differences in gene expression for GABA receptors or NMDA receptors. Morevoer,
growth associated protein 43, GAP-43, a protein that is necessary for neuronal growth cones as
well as long term learning has been found to be critical for axon and presynaptic terminal
formation and retention in other studies, but hippocampal gene expression in our study showed
no significant alteration after exposure to various maternal melatonin levels. However, ARNTL
is a key regulatory component of clock genes and the circadian cycle so that alterations in the
expression of thi critical gene may lead to critical changes in neuronal growth and plasticity. Our
data support the conclusion that the manipulation of maternal melatonin levels alters the brain
development and the circadian cycles that may lead to physiological and behavioral
abnormalities in adult offspring.

INTRODUCTION
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The Circadian Rhythm in Mammals
The circadian rhythm in mammals is the daily behavioral rhythm that is primarily
controlled by the fluctuating levels of serotonin and melatonin. Disruption in the stability of
these two neurohormones is one of the critical factors in psychopathological disorders in
humans. For instance, changes in melatonin levels have been shown in schizophrenia (Rao et al.,
1994), and depression (Kennedy et al., 1989) as well as other mood disorders (Srinivasan et al.,
2006). It is known that melatonin is a key player in maintaining a healthy daily rhythm; however,
it is not clear how abnormal fluctuations of this neurohormone influence the brain and relate to
brain-related diseases.
Melatonin is synthesized from serotonin and secreted by the pineal gland during the dark
period of the light-dark cycle under normal environmental conditions (Cardinali and Pevet,
1998). It is produced via a multi-step pathway beginning with the synthesis of 5hydroxytryptophan from tryptophan via tryptophan hydroxylase. The 5-hydroxytryptophan is
converted to serotonin by aromatic amino acid decarboxylase and the acetylation of serotonin by
arylalkylamine N-acetyltransferase results in N-acetylserotonin. The final step involves
hydroxyindole-O-methyltransferase which converts N-acetylserotonin to melatonin (Simonneuax
et al., 2003). The synthetic melatonin receptor antagonist, luzindole, has a structure that is very
similar to melatonin but with an additional benzyl group. This compound has been shown to
competitively antagonize the melatonin receptors at a presynaptic level (Dubocovich., 1988).

Figure 1: Simplified diagram of the circadian rhythm monitored by suprachiasmatic
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nucleus (adapted from Drake, 2010). Light induces retinal ganglion cells to signal to the
suprachiasmatic nucleus along the retinohypothalamic tract. The suprachaiasmatic nucleus,
which contains the primary circadian molecular clock processes inputs from the retinal ganglion
cells as well as other brain regions and elicits the release of melatonin by the pineal gland on top
of outputs to other brain regions. Melatonin is then released into the cerebrospinal fluid and
blood, spiking in levels at night.
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Figure 2: Diagram of melatonin synthesis (a) (adapted from Koch et al., 2009) and
molecular diagram of melatonin receptor antagonist, luzindole (b). Within the pineal gland,
5-hydroxytryptophan is synthesized from tryptophan by tryptophan hydroxylase. 5-HTP
decarboxylase transforms 5-HTP into 5-HT, or serotonin. Acetylation of serotonin by
arylalkylamine N-acetyltransferase produces N-acetylserotonin. Melatonin is produced from Nacetylserotonin by hydroxyindole-O-methyltransferase.
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(a)

(b)
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The secretion of melatonin is controlled by the circadian clock within the suprachiasmatic
nuclei (SCN) and is entrained to a light-dark cycle that is roughly 24 hours long (Claustrat et al.,
2005). SCN activity is responsive to the amount of light from the environment via signals from
the retinal ganglion cells that project through the optic chiasm and onto the SCN. The SCN then
projects indirectly to the pineal gland, where it is able to control the nightly secretion of
melatonin. Cells in the SCN are also capable of responding to the pineal gland’s melatonin
secretion via melatonin receptors. Hence, SCN control of melatonin secretion occurs through a
feedback loop that consists primarily of inputs from the retinal ganglion cells, but also from
endogenous melatonin secreted from the pineal and acting back on the SCN.

Clock Genes
Within the SCN, a circadian rhythm is generated by the oscillations in various regulatory
protein levels. Brain and muscle aryl hydrocarbon receptor translocator (ARNT)-like (BMAL1)
and Circadian Locomotor Output Cycle Kaput (CLOCK) form a heterodimer that binds to Eboxes which are regulatory sites within the sequence of DNA that allows the expression of
Period (PER) and Cryptochrome (CRY) mRNA as well as other clock controlled genes. PER and
CRY protein form a dimer (PER/CRY), which then feedback to inhibit the BMAL1/CLOCK
dimer function (Okamura et al., 2002). Furthermore, inhibition of the BMAL1/CLOCK cycle is
also conducted by a protein known as nuclear receptor subfamily 1, group D, member 1
(NR1D1). NR1D1 works by indirectly inhibiting the expression of the BMAL1 gene by blocking
its transcription, thereby decreasing the amount of BMAL1 protein (Layeghifard et al., 2008).

Figure 3: Simplified model of clock gene network in the suprachiasmatic nucles of
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mammals (adapted from Richter et al., 2004). BMAL1/CLOCK heterodimer binds to E-boxes
on the DNA transcribing clock genes and clock controlled genes. Clock genes, PER1 and CRY
form a dimer that then blocks BMAL1/CLOCK from binding to the E-box, thereby inhibiting
transcription of the clock genes and clock controlled genes.
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Figure 4: Simplified model of clock gene network in the suprachiasmatic nucles of
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mammals in relation to NR1D1’s inhibitory effects on BMAL1 (adapted from Sukumaran
et al., 2010). NR1D1, noted as REVERB in diagram, has inhibitory effects on the transcription
of BMAL. High levels of REVERB will inhibit the transcription of BMAL, thereby decreasing
the possibility of forming a BMAL/CLOCK heterodimer, affecting the level or protein
production.
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The fluctuating concentration differences of the BMAL1/CLOCK dimer in relation to the
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PER1/CRY dimer created by the activation and repression of downstream gene targets are what
create circadian rhythm within the SCN.

Melatonin and the Circadian Rhythm
There are two main hypotheses of how melatonin peaks are positively correlated with the
length of the dark phase during the light-dark cycle. In what is known as the “duration
hypothesis”, the duration of the nocturnal melatonin peak is considered to be the critical
parameter in understanding the light phase of the light-dark cycle (Cardinali and Pevet, 1993). In
contrast, the “coincidence hypothesis”, states that circadian variation of sensitivity to melatonin
is involved with the light response. When intact Syrian hamsters were kept at long photoperiods
and administered exogenous melatonin, their circadian response modeled those that were kept at
normal photoperiods, indicating that the exogenous melatonin advanced the circadian sensitive
phase (Stetson and Watson-Whitmyre, 1985). It is unclear whether or not either of these
hypotheses is an accurate explanation for SCN interaction with the photoperiods and regulation
of melatonin levels; however, both hypotheses underline the ties between the SCN, photoperiods
cued by the retinal ganglion cells, and the melatonin that is released from the pineal gland.
In addition to its association with the daily behavioral rhythm, melatonin is also known to
be a regulator of various bodily functions that oscillate with the daily cycle of light and dark. For
instance, core body temperature in humans, which exhibits a maximum during the day and a
minimum at night, has been shown to be coupled with the sleep-wake cycle in normal conditions
(Cagnacci et al., 1992). Experiments have also been conducted for those suffering from insomnia

or circadian rhythm disorders and the data show that low-dose melatonin treatments promoted
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regulation in sleep onset and sleep maintenance without disrupting other functions associated
with circadian rhythm (Zhdanova and Tucci., 2003; Sack et al., 1998). It is clear that melatonin
is a key player in the regulation of the circadian rhythm and multiple physiological functions. In
fact, evidence suggests that alternations in melatonin regulation may increase the risk for mood
disorders and cognitive dysfunction (Kripke et al., 2009). One study showed that depressed
patients exhibited clear circadian rhythm abnormalities that consisted mainly of melatonin
amplitude reduction at night (Souetre et al., 1988). In addition, differences in photoperiods and
the respective levels of melatonin were compared across generations in a maternal-fetal
chronobiological study. This investigation found that reduced melatonin concentrations impaired
in the animal’s ability to regulate internal temperature and had detrimental effects on immature
hippocampal neurons in animals (Schwartz, 2011).

NMDA Receptors
Mounting evidence suggests that detrimental effects of altered melatonin levels occur
when circadian rhythms are disturbed. For example, schizophrenic patients, who have altered
melatonin levels, also show impairments in memory and learning. Many of these changes have
been correlated with changes in key proteins that mediate synaptic function. For example, levels
of key postsynaptic receptors, subunits of a major glutamate receptor, the n-methyl-D-asparate
(NMDA) receptor, have been shown to be differentially expressed in schizophrenic patients with
right/left hemisphere differences (Vrajova et al., 2010). Studies show that melatonin alters
NMDA subunit concentrations in a dose-dependent manner leading to the possibility that the
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differences in concentration of NMDA subunits are linked to the alterations in NMDA receptor
function (Sutcu et al., 2006). Since these receptors are key mediators of learning and memory,
abnormalities in these functions are likely candidates for disturbances linked to mood disorder
and schizophrenia.

GABA Receptors
Additional synaptic disturbances have been associated with other major synaptic
receptors. For example, in contrast to glutamate’s excitatory role, the neurotransmitter gammaaminobutyric acid (GABA) is the main inhibitory neurotransmitter in the mammalian central
nervous system. GABA receptors can be broken down into two groups of receptors, ionotropic
(GABAA) and metabotropic (GABAB), and these receptors have been shown to influence
circadian rhythm, primarily through regulation of cell activation or inactivation, and to contribute
to jet-lag symptoms and phase-shifting (Golombek et al., 1996). With regard to the clock genes,
the effects of GABA on individual clock cells have been studied with results indicating that
GABA acting through its type A receptors is involved in phase shifting and synchronization of
clock cells (Liu and Reppert, 2000). Although the interactions between GABA and other
neurotransmitters in mood disorders such as schizophrenia are not entirely understood,
abnormalities in GABA interactions are associated with schizophrenia (Wasserf et al., 2003). It
has also been shown that GABAergic projection from the SCN to the dorsomedial hypothalamus
controls the release of melatonin during the dark phase (Kalsbeek et al., 1996). It is possible that
changes in melatonin levels may be coupled to the altered levels of GABA in schizophrenia.
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In summary, the synthesis and release of melatonin during prenatal development, a period
of time when circadian rhythms are being established, is central to an individual’s health.
Moreover, accurate regulation of melatonin levels is also critical during postnatal development.
This is especially true in the hippocampus, a brain region where acquisition and consolidation of
learning and memory take place. Hippocampal lesions have been used to demonstrate the
importance of the hippocampus for short-term and temporal memories in humans (Scoville and
Milner, 1957). In addition, hippocampal lesions result in behavioral disinhibition and reduced
anxiety (Bannerman et al., 2004). An altered synaptic circuitry within the hippocampus and its
extrinsic connections has also been associated with aberrant functional connectivity in
schizophrenic individuals (Harrison, 2004). These observations suggest that melatonin may
regulate neuronal plasticity (El-Sherif et al., 2003) and cell survival of new neurons (RamirezRodriguez et al., 2009), which are required for hippocampal and cognitive function in adult rats.

Hypothesis
Altering maternal melatonin levels via exogenous melatonin treatment during pregnancy
leads to differential mRNA gene expression in adult offspring for gene products mediating the
proper control of the circadian rhythm.

MATERIALS AND METHODS
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Animals and Tissue Collection
Eleven pregnant Sprague-Dawley dams from Hilltop Laboratories were randomly
assigned to three treatment groups. The control group was injected with a vehicle containing
50%(volume/volume) sterile, filtered DMSO (Sigma Aldrich, St. Louis, MO) in distilled water.
The melatonin group was injected with 5mg/kg melatonin (N-acetyl-5-methoxytryptamine)
(Sigma Aldrich). The luzindole group was injected with 5mg/kg luzindole (N-acetyl-2benzyltryptamine) (BA Chemicals, London, UK), a nonselective melatonin receptor antagonist
(Dubocovich, 1998). All drugs were administered subcutaneously at a volume of 0.05 to 0.06mL
prior to the dark cycle at 1600 to 1800 for 5 days from days 14 to 18 of gestation. Dams were
housed individually, given food and water ad libitum and kept at a controlled temperature of
23°C under a strict 12hour light-dark cycle.
Offspring were weighed at birth, and on postnatal day 21, male offspring from the same
treatment group were housed in pairs. Every 5 to 7 days, body mass per rat and food intake per
cage were measured from weaning to sacrifice. After 120 days, half of the animals were
sacrificed at 0000 hours and the rest were sacrificed at 1200 hours. Right and left hippocampi
were dissected from each brain. (All animal protocols used were in accordance with the NIH
Guide for Care and Use of Laboratory Animals and reviewed and approved by the Animal Care
and Use Committee of Bucknell University).
Prior to reverse transcription, total RNA was extracted from the hippocampus of
individual 120-day old male rats and purified using TRIzol (Invitrogen, Carlsbad, CA). Total
RNA was then reverse transcribed using a RETROscript kit (Ambion, Austin, TX). Primers were

designed with the online NCBI database and confirmed with BLAST and then ordered from
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MWG Oligo Synthesis (High Point, NC). Real-time PCR was performed in 96-well optical
plates with 0.05µM of forward and reverse primers, cDNA from 2µg RNA input (diluted 1:50)
and 12.5µL Supermix (Bio-Rad, Hercules, CA). The assay was conducted using the iCycler iQ
Real Time PCR Detection System (Bio-Rad, Hercules, CA).

Primer Design, RT-PCR and Analysis
Efficiency of the primers was determined using a serial dilution of RT-PCR products.
Efficiencies were calculated using the following formula:

Prior to analyzing experimental plates, control plates for each primer pair were analyzed
by testing randomly selected samples, samples not containing cDNA, or dH2O. Primer pairs that
showed a high efficiency of amplification and “clean” control plates were then run on gel
electrophoresis with 12% Boraid to ensure that there was no DNA contamination. Clean controls
are defined such that: randomly selected samples, samples not containing cDNA, and samples
with dH2O only did not display a fluorescence peak before 35 cycles. Final genes of interest
were selected only when the two criteria 1) clean controls confirmed by gel electrophoresis and
2) high efficiencies were met. RT-PCR on samples were conducted using a thermocycling
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program of 3’ at 95⁰C, 40x15’’ PCR cycles at 95⁰C, 1’ at 60⁰C , 1’ at 55⁰C and concluded with

80x15’’ with a temperature ramp of 0.5⁰C/repeat where dissociation curve data were collected to
ensure that only target sequences were amplified.
The following genes were amplified from the hippocampus-derived cDNA: glutamate Nmethyl-D-aspartate receptor (GRIN) subunits (GRIN1, GRIN2A, GRIN2B), gammaaminobutyric acid (GABA) A receptor 2-2 (GABAA2-2), gamma-aminobutyric acid (GABA) B
receptor 1 (GABAB1), growth associated protein 43 (GAP43), neural cell adhesion molecule 1
(NCAM1), aryl hydrocarbon receptor nuclear translocator-like (ARNTL) and nuclear receptor
subfamily 1 member 1 (NR1D1). Each gene was co-amplified with succinate dehydrogenase
complex subunit A (SDHA), a housekeeping gene to control for any pipetting errors.
Two negative controls were conducted to ensure that there was no contamination in both
primers and samples. RT-PCR was conducted for each primer pair where cDNA samples were
substituted with dH2O to verify that there was no DNA contamination with the primers.
Additionally, gel electrophoresis was conducted to reconfirm the lack of DNA contamination in
the primers. RT-PCR was also conducted for each primer pair where cDNA was substituted with
RNA to verify no DNA contamination of the primer samples. Efficiencies for each primer pair
were conducted for those primer pairs with clear negative controls.
Triplicates of each sample were run and assigned cycle threshold (CT) values.
Differences in CT (dCT ) were determined by subtracting the CT SDHA from CT for the genes of
interest. The treatment/time group with the highest dCT was set to zero and the dCT for each
group was subtracted from the group with the highest dCT which was used to calibrate the others

(ddCT ). The ddCT values were calculated as powers of 2 (2^ ddCT ) to account for exponential
doubling during PCR and to provide a relative measure of gene expression for each gene.
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Table 1: Primer Sequences used in real-time PCR (NCBI)
Primer ID

Primer Sequence 5’-3’

Accession No.

Length, nt

SDHA

Fwd: CGGGGTTGGCGCAGTTTCGA

NM130428.1

134

NM017010.1

93

NM012573.3

113

NM012574.1

94

Rev: AAGTGAAAGCCACGAGTCGCCC
GRIN1

Fwd: CTGCTGGACCGCTTCAGTCCC
Rev: CCGGAGTTGAGCAGGACGCC

GRIN2A

Fwd: TCAGTGCCTCCGTCTGGGTGA
Rev: GCCCGTGGGGAGCTTCCCT

GRIN2B

Fwd: ATGCAAGCGAGAAGAGGACCCTGG
Rev: CTTCAGCTAGTCGGCTCTCTTGGT

GABAA2-2

Fwd: GTGGAACCCAGCCAGGTTGGTG

NM001135779.1 136

Rev: GCTGTCTCCCAGTCCTGGTCTAAGA
GABAB1

Fwd: GCCCCACTGCCAGGTGAATCG

NM031028.3

82

NM017915.3

136

NM031521.1

130

NM024362.2

94

Rev: GCCCCCGCTCATGGGAAACA
GAP43

Fwd: CCAAGCTGAGGAGGAGAAAGAAGCT
Rev: GGGGCAACGTGGAAAGCCGT

NCAM1

Fwd: CCAGCGCACCCAAGCTGGAA
Rev: TCGGAGGCGAGCGCTCTGTA

ARNTL

Fwd: GAGCGGTTTGCCAGTCGGA
Rev: CCGTCGCCGCCGCTCTATTT

NR1D1

Fwd: CATTGCCCACGGGGCGAGAG
Rev: ACACCACCTGTGTTGTTGTTGGAGT

Final concentration of each primer was 1µM

NM001113422.1 124

RESULTS
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Effects of Altered Prenatal Melatonin Signaling on Litter Size, Litter Composition, Growth
and Feeding Patterns
The difference in effects of administration of vehicle, 5mg/kg melatonin, or 5mg/kg
luzindole to pregnant dams from days 14-18 of gestation on litter size and birth male body mass
were not significant (Table 2). Despite the lack of significance, the effect of treatment on litter
size was approaching significance for a decrease in litter size for melatonin-treated dams
compared to luzindole-treated dams, both in respect to the litter size for control dams (P=0.060
for melatonin, P=0.0805 for luzindole).
Body mass and food intake were monitored for male rat litters treated prenatally with
vehicle, melatonin, or luzindole (Figure 5). The body mass curve for litters treated prenatally
with melatonin was significantly increased from those treated prenatally with vehicle or
luzindole (P=0.00171 for reduced control and melatonin model to full control and melatonin
model, P=.01084 for reduced melatonin and luzindole model to full melatonin and luzindole
model, where growth data over time was averaged by litter, and linear regression analysis was
performed by comparison of full and reduced models for body mass and food intake by treatment
with family-wise Bonferroni correction). No significant effect on food intake was found in
response to prenatal treatment.
In addition, prenatal treatment did not have significant impact on percentage of body fat,
left hippocampus mass, right hippocampus mass or left hippocampus mass to right hippocampus
mass ratio.
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Table 2: Litter size and average mass of male pups per litter for dams treated with vehicle
(CON), 5mg/kg melatonin (MEL) or 5mg/kg Luzindole (LUZ) during days 14-18 of
gestation

Litter size
(Pups)

Average Male Mass
(g/pup per litter)

Control (CON)

14.3 ± 0.9

12.7 ± 1.0

Melatonin (MEL)

11.8 ± 0.6

13.5 ± 0.9

Luzindole (LUZ)

14.8 ± 0.9

11.8 ± 1.5

CON-MEL-LUZ

P=0.060

P=0.618

CON-MEL

P=0.197

P=1.00

CON-LUZ

P=1.00

P=1.00

MEL-LUZ

P=0.085

P=1.00

Figure 5. Average body weights and food intake of male rats from dams treated with
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vehicle, melatonin, or luzindole. Average body mass (a) and food intake (c) of 11 litters
(Control n=3, Melatonin n=4, Luzindole n=3) measured from postnatal day (PD) 21 to PD 120.
Litters treated with prenatal melatonin were found to have body mass curves significantly
different from controls and Luzindole treated litters, (**P<0.01, *P<0.05) respectively. No
significant effect of prenatal treatment on food intake was found.
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Table 3: Percent body fat, left and right hippocampus mass, and ratio of left hippocampus
mass to right hippocampus mass at sacrifice for male rats from dams treated with vehicle,
melatonin and luzindole.

Percent Body
Fat (fat/body
mass)

Left
Hippocampus
Mass (mg)

Right
Left Hippocampus/
Hippocampus
Right Hippocampus
Mass (mg)
Mass

Control (CON)

3.54 ± 0.16

75 ± 3

74.8 ± 1.8

1.01 ± 0.04

Melatonin (MEL)

3.4 ± 0.3

76 ± 3

75 ± 2

1.03 ± 0.03

Luzindole (LUZ)

3.46 ± 0.14

72.4 ± 1.3

72.8 ± 1.5

1.01 ± 0.03

CON-MEL-LUZ

P=0.855

P=0.411

P=0.651

P=0.901

CON-MEL

P=1.00

P=1.00

P=1.00

P=1.00

CON-LUZ

P=1.00

P=1.00

P=1.00

P=1.00

MEL-LUZ

P=1.00

P=0.606

P=1.00

P=1.00

Effects of Altered Prenatal Melatonin Signaling on Hippocampal Gene Expression
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Primers of targeted genes were tested for DNA contamination by running RT-PCR using
selected cDNA samples, DNA-free samples, and dH2O substituted for normal samples. Gel
electrophoresis was conducted to insure the clarity of chosen primers (Figure 6). Primers that
showed clarity by having single bands appear only on the RT+ lanes were then tested and
efficiency was calculated using a small dilution of selected samples (Figure 7, Table 4). Nine
primers with the highest efficiencies were chosen to be tested on experimental samples.
Hippocampal gene expression in the hippocampi of male rats prenatally treated with
vehicle, melatonin and luzindole were analyzed (Figure 8, Figure 9). Analysis of gene expression
between sides of the hippocampus (right vs. left) within two distinct time periods (noon vs.
midnight) failed to produce significant difference in circadian expression (data not shown).
Analysis of gene expression between two distinct time periods (noon vs. midnight) showed close
to significant differences for the ARNTL gene (P=.09 for control vs. melatonin at noon and
P=0.088 for noon vs. midnight for control group). Trends were observed in other genes albeit
there was no significant difference amongst the groups or times for all genes, altered melatonin
levels, whether they were increased with additional melatonin or decreased with luzindole
administration.
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Figure 6: Representative gel image photographed after gel electrophoresis was performed.
a) Gel 1: 1) Ladder; 2) GRIN1A RT-; 3) GRIN1A RT+; 4) GRIN 1A S-; 5) GRIN2A RT-; 6)
GRIN2A RT+; 7) GRIN2A S-; 8)GRIN2B RT-; 9)GRIN2B RT+; 10) GRIN2B S-; b). Gel 2: 1)

SDHA S-; 2)SDHA RT+; 3)SDHA RT-; 4)GAP43 S-; 5)GAP43 RT+; 6)GAP43 RT-; 7) Ladder.
RT- denotes DNA-free samples, RT+ denotes cDNA samples and S- denotes dH2O samples.

(a)

(b)
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Figure 7. Representative Efficiency Curve.* Efficiency curves were determined through a
serial dilution of selected samples that were run using the RT-PCR mix. Efficiency was
calculated raising 10 by the negative reciprocal of the slope. *SDHA primer efficiency is
displayed.
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Table 4: Efficiencies of primers.
Gene

Intercept

Slope

R2

Efficiency

ARNTL

33.724

-3.5614

0.98942

1.77

NR1D1

33.978

-3.6019

0.97755

1.78

GRIN1

29.047

-3.4022

0.9817

1.97

GRIN2A

31.442

-4.2103

0.9968

1.73

GRIN2B

30.576

-3.9476

0.9958

1.79

GABAA

32.0489

-4.8930

0.9670

1.60

GABAB

33.969

-4.1727

0.9971

1.74

GAP43

30.629

-4.1484

0.9834

1.74

NCAM

29.007

-3.5194

0.99381

1.95

SDHA

29.889

-3.4286

0.9957

1.96

Figure 8. The effects of prenatal melatonin or luzindole on adult male rat hippocampal
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gene expression. Relative cycle number of fluorescence for hippocampal cDNA during RT-PCR
with primers for GRIN1, GRIN2A, GRIN2B (a); GABAA, GABAB, GAP43 (b); NCAM1,
ARNTL, NR1D1 (c).

(a)

(b)

(c)
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Figure 9. Relative gene expression of ARNTL (a), NR1D1V (b), GRIN1 (c), GRIN2A (d),
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GRIN2B(e), GABAA (f), GABAB (g), GAP43 (h), and NCAM1-1 (i), in hippocampal tissues
from adult male rats exposed to melatonin or luzindole in utero compared to controls.
Animals were sacrificed at noon or midnight. Values are expressed in relative expression with
the group expressing the lowest level of each target gene evaluated set to 1.
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*P<0.1compared to Control at Noon. †no significant difference between Control at noon,
Luzindole at noon and Luzindole at midnight.
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This study was designed to test the effects of altered maternal melatonin levels on
hippocampal gene expression in adult male rat offspring. Existing research in this field is very
limited, however, we are adding our data to the literature and were able to develop an
explanation for our observations.

Melatonin and the Hippocampus
Melatonin has two main receptors MT1 and MT2, both of which have been found in
various regions within the hippocampus, including the dentate gyrus, CA3 and CA1 regions
(Musshoff et al., 2002). In a previous study conducted by my fellow student, Joshua Ripple,
behavior experiments including the open field test, Morris water maze, and elevated plus maze
were conducted. Rats that were exposed to higher prenatal melatonin levels showed increase in
rearing in the open field test and an increased right turn preference in the elevated plus maze. On
the other hand, rats exposed to prenatal luzindole displayed greater freezing and grooming
behavior in the open field test and improved learning in the Morris water maze. Using the same
samples used in this study, gene expression for both melatonin receptors was measured in a
similar fashion using rt-PCR. For the offspring whose mother received the exogenous melatonin,
MT1 gene expression was significantly higher than in the control and luzindole group. In
addition, MT1 gene expression was significantly higher compared to MT2 gene expression for all
three experimental groups (Ripple, 2010). The alterations in circadian rhythm may, in part, be
explained by this increase in MT1 gene expression associated with the increased melatonin levels
and ARNTL gene expression found in our study.

Melatonin has also been studied as a contributor to learning, memory, and
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psychopathological disorders that depend on neuronal plasticity processes in the hippocmpus.
Alterations in melatonin receptor concentration have been observed in various
psychopathologies. For instance in Alzheimer’s disease (AD), a significant increase in MT1
receptors have been found, possibly as a regulatory response to the impaired melatonin levels in
AD individuals (Savaskan et al., 2001). Additionally, MT2 receptors are significantly decreased
in AD patients, suggesting that MT2 receptors are mediated by melatonin in the hippocampi of
humans (Savaskan et al., 2005). Such findings have led to possible therapeutic approaches that
involve supplementing antidepressant treatment with some type of melatonin receptor agonist. It
is thought that the ratio of MT1/MT2 receptors may contribute to improving antidepressant effects
(Hirsch-Rodriguez et al., 2007).
Unlike MT1, MT2 receptors have been shown to have inhibitory effects on long-term
potentiation (LTP) using the elevated plus-maze as observed in mice where inhibitory actions of
melatonin were lost in those deficient in MT2 but not in MT1 (Larson et al., 2006). Furthermore,
administration of luzindole was seen to prevent the inhibition of LTP by melatonin via the MT2
receptors (Wang et al., 2005). However, melatonin’s inhibitory characteristics were not seen in
the MT1 receptors thereby suggesting opposing receptor activity for the two melatonin receptors
(Musshoff et al., 2002).
Previously, it was found that the lasting effects of overexpressed melatonin levels in
utero show an increase in MT1 receptors but not in MT2 receptors; thus the increased melatonin
receptor ratio is similar to that shown in AD individuals. In addition, it has been shown that
altered maternal melatonin levels significantly affect brain function in offspring. For example, at
postnatal day 9, offspring of pinealectomized Wistar rat dams had reduced melatonin receptor

gene expression in their brains (Zitouni et al., 1995). In addition, exogenous melatonin
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administration in pinealectomized Swiss albino rats showed inhibition of harmful effects of
epilepsy, thereby allowing proper hippocampal development in the offspring (Turgut et al.,
2006).
Melatonin and Clock Gene Expression
In addition to the melatonin receptors, the aryl hydrocarbon receptor nuclear translocatorlike (ARNTL) gene in the rat contributes to circadian rhythm generation. This gene is considered
to be an ortholog to the brain and muscle aryl hydrocarbon receptor nuclear translocator 1
(BMAL1) protein in humans, which forms a heterodimer with the circadian locomotor output
cycles kaput (CLOCK) protein. The BMAL1/CLOCK heterodimer then is a critical regulatory
component since it binds to a promotor region, the E-box, which allows for the transcription of
many genes including those associated with circadian rhythm, the period (PER) and
cryptochrome (CRY) genes (Gekakis et al., 1998; Sangoram et al., 1998). PER and CRY, in their
protein form, also form a dimer. PER is known to be a positive regulator of the circadian loop,
but CRY is known to be a negative regulator (Shearmen et al., 2000). Hence, the increase in
CRY concentration would lead to an inhibition of the BMAL1/CLOCK dimer, which then
decreases the rate of transcription of PER and CRY. As PER/CRY protein levels increase, they
form a dimer that exerts negative feedback in this loop. When concentrations of PER and CRY
are low, BMAL1/CLOCK form a dimer to allow transcription. This fluctuation of protein
production creates the circadian rhythm within the SCN.
Irregularities in the oscillation of clock gene expression lead to arrhythmic circadian
systems that have been associated with physiological dysfunction. For example, synchronized

44

circadian cycle was absent in Wistar rats following a 30-day exposure to continuous light. This
disruption was especially apparent for BMAL1, which was no longer expressed in synchrony
with other clock genes (Novakova et al, 2011). Moreover, low amplitude PER gene expression
was observed using in situ hybridization and was associated with the lack of intercellular
synchrony, which is critical for generating circadian rhythm. In our study, the high BMAL1
expression detected in the offspring from treated dams exposed to melatonin at noon may

increase the risk of arrhythmic circadian cycles, as the BMAL1 expression at noon did not differ
from the BMAL1 expression at midnight in these animals. In contrast, the offspring from control
rats exhibited a significantly higher expression of BMAL1 at midnight. In contrast to both of
these groups, Luzindole decreased the expression of BMAL1 at both time points.
Our finding is interesting considering that melatonin is an important regulator of
rhythmic clock gene expression in mice. For example, loss of melatonin receptors and the effect
this loss had on clock gene expression was studied using melatonin 1-receptor knockout and
melatonin 2-receptor knockout mice (Von Gall, 2005). Using in situ hybridization and western
blotting, gene expression was analyzed in the hypophyseal pars tuberalis, one of the main target
regions for melatonin. In this study, they found that gene expression of PER1, CRY1, CLOCK
and BMAL1 were dramatically reduced only in the melatonin 1-receptor knockout mice. This
indicates that melatonin, through its melatonin 1-receptor, has regulatory effects on critical clock
genes such as PER and CRY, and most likely BMAL1, thereby playing a crucial role in
regulating and maintaining circadian rhythm.
Another study that directly relates to our study is one in which maternal melatonin levels
were manipulated in pregnant Capucin monkeys. Suppression of maternal melatonin and
addition of maternal melatonin resulted in offspring that exhibited lowered clock gene expression

in the fetal SCN (Torres Farfan et al., 2006). Hence, altering melatonin levels in utero has
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significant effects on circadian rhythm development and clock gene expression, which include
the expression of BMAL1, PER2, CRY2 and CLOCK. Since fetuses rely on their mother’s
hormonal levels to establish bodily functions like circadian rhythm and endocrine modulation
(Tamura et al., 2008), altering the melatonin levels during gestation can lead to critical changes
in the fetal clock gene expression.
The full consequences of altered fetal clock gene expression and changes in circadian
rhythms are unknown. However, it is known that BMAL1 and PER proteins have other
properties apart from their function as the circadian oscillator. For example, they participate in
essential non-redundant regulatory roles during tissue homeostasis and aging (Kondratov, 2007).
Not only is there a loss of circadian rhythm if BMAL1 is underexpressed or if there are
irregularities in BMAL1 availability, but, it has been reported that such mice also exhibit
premature aging (Bunger et al., 2005; Kondratov et al., 2006; Nadon, 2006). Characteristics of
progeria, such as disruptions in control of glucose and fat metabolism, homeostasis and
modulation of genotoxic stress have all been seen in BMAL1 knockout mice (Rudic et al., 2004;
Shimba et al., 2005).
Decreased melatonin levels are often found in individuals with depression or related
psychopathological disorder, like bipolar disorder (Kennedy 1996). In a small sample of US
individuals with psychopathological disorders, such as bipolar 1 disorder, schizoaffective
disorder, and schizophrenia, a significant association was found between the reduction in
BMAL1, Timeless and PER3 concentrations compared to CLOCK (Mansour, 2005). Moreover,
in a circadian clock gene study that evaluated ten genes, haplotypes in BMAL1 and PER3 were
assessed to have significant association with bipolar affective disorder (Nievergelt 2006). Hence,

it can be said that bipolar disorder is very closely associated with the malfunctioning of the
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circadian rhythm, in part due to abnormal melatonin levels, even at the molecular level.
The nuclear receptor subfamily 1, group D, member 1 (NR1D1), is the gene for RevErbA, a protein that regulates cellular proliferation and differentiation that is coupled to the
circadian rhythm through associations with BMAL1. NR1D1 has been identified as an orphan
nuclear receptor and is the major regulator of cyclic BMAL1 transcription via the negative
feedback that is exerted by PER/CRY dimer (Preitner et al., 2002). More specifically, NR1D1
has been found to act as a transcriptional inhibitor at the E-box DNA sequence that functions as
response elements for the core circadian-clock components of CLOCK and BMAL1
(Triqueneaux et al., 2004). Most importantly, however, it has been determined that NR1D1
transcription is rhythmic within the hippocampus of rats, primarily due to fluctuations in CRY
concentration, which is controlled by the BMAL1/CLOCK protein (Valnegri et al., 2011). The
importance of NR1D1 in development has been seen in the cerebellum of mice lacking the
NR1D1 gene where unexpected abnormalities including alterations of the Purkinje cell
development and delays in proliferation and migration of granule cells were observed (Chomez
et al., 2000). NR1D1 is also a target of interest for drug treatment for certain psychopathological
disorders. In bipolar disorder, lithium is commonly used to alter the circadian rhythm by
inhibiting the glycogen synthase kinase 3 (GSK3) which leads to degradation of NR1D1 and
thereby activation of BMAL1 (Yin et al., 2006). Altered levels of NR1D1 have been seen in
patients who had disturbed sleep and therefore altered circadian rhythms, which are undoubtedly
impacted by abnormal levels of melatonin (Wulff et al., 2009). In our study, the lack of
significant difference in the NR1D1 gene expression observed by alteration of melatonin levels
in utero seems to indicate that the effects on BMAL1 were not large enough to significantly alter

the production of CRY proteins that would then affect NR1D1 expression, or that some other
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component critical to BMAL1 transcriptional regulation is involved. Although clear associations
between melatonin levels and NR1D1 have not been seen as of yet, alterations in external
melatonin levels during development will most likely have an effect on fetal development as
NR1D1 has already been seen to have effects with altered melatonin levels.
Melatonin and Cognitive Function
Long-term plasticity has been associated with the activity of the glutamate NMDA
receptors which are present in high concentration in the hippocampus (Collingridge and Bliss,
1987; Herron et al., 1986; Bashir et al., 1993). These metabotropic glutamate receptors have
been shown to be required for hippocampal long-term potentiation to occur within the
hippocampus (Malenka and Nicoll, 1993). The NMDA receptor is a heterotetramer made up of
two GluNR1 and two GluNR2 subunits (either GluNR2A or GluNR2B). In situ hybridization has
shown that the three subunits are expressed in different concentrations throughout the various
hippocampal subfields with GRIN1 having the most even expression throughout the
hippocampus, possibly due to the fact that GRIN1 must be present to form the NMDA
heterodimer (Xu et al., 2002).
Studies have also shown that melatonin has different effects on LTP, as melatonin in the
CA1 region blocked LTP while melatonin injected into the CA3 region barely reduced LTP
(Ozcan et al., 2006). In relation to melatonin, in a study where melatonin was administered for
four weeks, concentrations of NMDA receptor subunits 2A and 2B were found to increase within
the rat hippocampus (Sutcu et al., 2005). Furthermore, melatonin exhibited partial protective
effects on the NMDA receptor subunits 2A and 2B on rats given ochratoxin A, a mycotoxin that
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accumulates in the brain and reduces NMDA receptor concentration (Delibas et al., 2003). The

protective capacity of melatonin was also shown in response to a challenge from quinolinic acid
degeneration of rat hippocampal neurons (Southgate et al., 1998).
In contrast to the excitatory effects of glutamate and its NMDA receptors on learning and
memory, GABA is the major inhibitory neurotransmitter with its receptor GABAR. There are
two main classes of GABA receptors - the ionotropic receptor GABAA and the metabotropic
receptor GABAB; both of the GABAA and GABAB receptors mediate inhibitory postsynaptic
transmission in the hippocampus (Kuffler and Edwards, 1958; Isaacson et al., 1993). Clinical
data seems to indicate that psychopathological disorders oftentimes involve decreased GABA
function where treatments have targeted an upregulation of GABAB receptor (Petty, 1995).
While there is little data on melatonin’s effect on GABA receptors, a connection between
melatonin’s ability to control excitability and GABA-containing neurons’ ability to inhibit
neuronal excitability has been proposed (Golombek et al., 1998; Acufla-Castroviejo et al., 2007).
Studies have shown that melatonin seems to participate in the regulation of the GABAbenzodiazepine receptor complex, but does not directly act on the complexes (Nilcs et al., 1987;
Rosenstein and Cardinali, 1990).
As previously mentioned, the exact interactions between altered melatonin and behavior
is scarce, but melatonin has been shown to be correlated with significant differences in proexploratory activity in rats that were tested using a plus-maze (Golombek et al, 1993). In
addition, a clinical study reported that melatonin co-administered during withdrawal periods of
hypnotic drugs have eased the discontinuation (Garfinkel et al., 1999). Moreover, forced
swimming induced behavioral despair tests have shown similar behavioral response from the rats
that underwent melatonin treatment and GABA-benzodiazepine receptor agonists (Raghavendra
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et al., 2000). This suggests that the antidepressant-like effect of melatonin is very similar to the
effect of GABA-benzodiazepine receptor agonists. If melatonin is having similar inhibitory

effects on neurons as GABA, this may account for the slight decrease in GABAA and GABAB in
gene expression, observed in the Melatonin-Noon groups in our study although this data did not
reach significance.
Synaptic plasticity, learning and memory also involve molecules like the neural cell
adhesion molecule (NCAM), which are members of the immunoglobulin superfamily and are
expressed on the surface of neuronal cells. Of the three NCAM forms, NCAM140 and
NCAM180 have shown a decrease in Wistar rats exposed to constant light for 7 days (Baydas et
al., 2002). In contrast, the rats that were administered melatonin for 7 days had increased levels
of NCAM140 and NCAM180 expression. Furthermore, injection of 10mg/kg of melatonin, twice
the amount used compared to our study, into the experimental rats as opposed to the dams
showed significant alteration in the gene expressions of different NCAM isoforms (Nedzvetsky
et al., 2003). In our study, altered maternal melatonin levels, on the other hand, do not seem to
alter NCAM140 expression in the offspring. However, the importance of melatonin was
supported in our study since the NCAM expression levels in the Luzindole-Noon and LuzindoleMidnight did not change at all whereas the controls exhibited a significant difference at these
two time points. These data shows the need for melatonin in the regulation of NCAM expression.
The growth-associated protein 43 (GAP43) is another important protein for neural
plasticity, especially during neuronal development. However, GAP43 has also been seen to play
critical roles in synaptic remodeling in adults, especially after lesions. Using in situ
hybridization, an increase in GAP43 mRNA expression was seen in the granule cells of
hippocampus in rats that underwent experimental lesions (Bendotti et al., 1994). Although there

has been no direct study on the effects of melatonin on GAP43 gene expression, studies have
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shown that melatonin has protective effects against neuronal degeneration by maintaining key
synaptic molecules, such as tyrosine hydroxylase, synaptophysic and GAP43 (Kaewsuk et al.,
2009). Morevoer, alterations in GAP43 have been detected in the brains of individuals with
psychopathological disorders. In a study on the hippocampi of schizophrenic patients,
quantitative immunoblots revealed that GAP43 is increased in association cortices as well as in
the hippocampi, as if it is one manifestation of the brain trying to compensate for the
perturbations of synaptic organization that schizophrenia is associated with (Perrone-Bizzozero
et al., 1996; Blennow et al., 1999). This evidence suggested that there might be a connection
between altered prenatal melatonin and GAP43 expression; however, we did not detect any
significant differences.
Circadian Rhythm During Development
Our study was designed to examine the importance of the maternal melatonin during fetal
brain development, in particular, the programming of “set points” for the expression of key genes
mediating hippocampal control of circadian rhythm. As fetuses are only exposed to their
mother’s hormone levels while in utero, the maternal circadian circuit becomes the basis for the
fetal circadian circuit. Hence, when the maternal circadian circuit was disturbed by the presence
of excess melatonin following its exogenous administration, or, suppression of melatonin
following the administration of luzindole, a significant change was observed in the offspring’s
expression of BMAL1, one of the key clock genes that control the circadian cycle. It is important
to note, however, that the altered levels of melatonin and consequent changes in hippocampal
BMAL1 gene expression did not have any significant effects on the expression of other genes
that have been reported to be changed by alteration in melatonin or circadian rhythm
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disturbances, including those for subunits of NMDA receptors as well as GABA receptors. This
could suggest that there are protective mechanisms in the mother or fetus that override the
influence of the particular dose of melatonin and luzinolde that were used in our study.
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